API manufacturing

R&D

Navigating development in a complex molecule world

For decades, the pharmaceutical industry has relied on accelerated development and manufacturing timelines to bring new therapies to patients quickly.

News

Rendering of planned Houston facility, via Eli Lilly

Lilly names Houston as site for $6.5bn API facility

Lilly has named Houston as the second of four locations for new manufacturing facilities that are central to a $27bn investment programme in the US.

R&D

Supply chain resilience in pharma: Delivering consistency am...

In an interconnected economy, industries operating on an international scale are increasingly vulnerable to supply chain disruption.

Navigating development in a complex molecule world

Lilly names Houston as site for $6.5bn API facility

Supply chain resilience in pharma: Delivering consistency am...

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

Editor's Picks